The supply of allograft Cryoskin for use in the treatment of burn injuries within the Burns Centre.
The allograft Cryoskin will be required to support clinical care by providing temporary wound coverage to promote healing, reduce pain, and minimise infection risk in patients with burns.
The contract will cover the provision, storage, and delivery of clinically approved allograft Cryoskin products in line with relevant regulatory, safety, and quality standards.
Suppliers must demonstrate proven experience in the supply of human tissue allografts and the ability to meet the specialised needs of a tertiary Burns Centre, including reliability of supply and adherence to clinical governance requirements.